Flow Cytometric Assessment of Myelodysplastic Syndromes/Neoplasms

Xueyan Chen; Ulrika Johansson; Sindhu Cherian

doi:10.1016/j.cll.2023.06.006

Flow Cytometric Assessment of Myelodysplastic Syndromes/Neoplasms

Clin Lab Med. 2023 Dec;43(4):521-547. doi: 10.1016/j.cll.2023.06.006. Epub 2023 Aug 7.

Authors

Xueyan Chen¹, Ulrika Johansson², Sindhu Cherian³

Affiliations

¹ Translational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, 825 Eastlake Avenue East, Seattle, WA 98109, USA.
² SI-HMDS, Haematology, UHBW NHS Foundation Trust, Bristol Royal Infirmary, Upper Maudlin Street, Bristol, BS2 8HW, UK.
³ Department of Laboratory Medicine and Pathology, University of Washington, 825 Eastlake Avenue East, Seattle, WA 98109, USA. Electronic address: cherians@uw.edu.

PMID: 37865501
DOI: 10.1016/j.cll.2023.06.006

Abstract

Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous class of hematopoietic stem cell neoplasms characterized by ineffective hematopoiesis leading to peripheral cytopenias. This group of diseases is typically diagnosed using a combination of clinical, morphologic, and genetic criteria. Many studies have described the value of multiparametric flow cytometry (MFC) in the diagnosis, classification, and prognostication of MDS. This review summarizes the approach to MDS diagnosis and immunophenotypic characterization using MFC and describes the current state while highlighting future opportunities and potential pitfalls.

Keywords: Flow cytometry; Immunophenotyping; MDS; Myelodysplastic syndromes/neoplasms; Myeloid maturation.

Publication types

Review

MeSH terms

Flow Cytometry
Humans
Immunophenotyping
Myelodysplastic Syndromes* / diagnosis
Neoplasms*